Condition: Healthy · Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd.
The aim of this study is to investigate the safety and tolerability of HB0056 in healthy subjects following single-dose.
This description comes directly from the study's public registry record.
Jingjing Wang · 086 15002154126 · jingjing.wang@huaota.com
Xiaoyan Liu · 086 15002154126 · xiaoyan.liu@huaota.com
Always discuss trial participation with your own doctor first.
| New Zealand Clinical Research | Christchurch, New Zealand | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06612970